Investment, Funding & Disinvestments
-
FDA clears AstraZeneca’s Imfinzi-BCG combo for high-risk bladder cancer
The decision expands Imfinzi’s bladder cancer footprint beyond its earlier approval in muscle-invasive bladder cancer (MIBC), where it is used with chemotherapy agents’ gemcitabine and cisplatin before surgery and as a monotherapy afterward.
-
Apogee Therapeutics secures US$1.3B Blackstone deal for phase 3 eczema drug
Under the deal, Blackstone Life Sciences will provide up to US$800 million in exchange for low- to mid-single-digit tiered royalties on future zumilokibart sales for 15 years.
-
Align Technology to set up US$200M Invisalign plant in Hyderabad
The facility, which is expected to begin operations in 2027, will become Align Technology’s first manufacturing site in India and its fourth worldwide.
-
Global Climate and Health Alliance urges WHO to integrate climate action into global health policies
The appeal followed discussions held during the 79th World Health Assembly (WHA79), where climate-related health risks featured prominently across several agenda items.
-
Moscow expands cancer diagnostics training with advanced self-healing biopsy simulators
The initiative supports Moscow’s broader oncology modernization strategy, which combines investments in diagnostic technology, artificial intelligence, and clinician education to improve patient outcomes.
-
Murang’a County deploys Starlink satellite internet in 170 health facilities to enhance rural healthcare
The ambitious project targets approximately 1.2 million residents, most of whom inhabit rural communities where traditional connectivity has remained inconsistent.
-
QCIL launches first local hydroxyurea production in Uganda
Health authorities estimate that approximately 20,000 babies are born with the condition each year, while nearly 30 percent of the population carries the sickle cell trait.
-
Eli Lilly expands vaccine pipeline with US$3.83B acquisition of three biotech firms
The acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company mark the drugmaker’s eighth, ninth, and tenth deals of 2026 as it continues to diversify beyond its blockbuster obesity and diabetes franchises.
-
Lantheus considers US$7B takeover offer from Curium Pharma
The proposed acquisition comes at a time when radiopharmaceuticals are attracting unprecedented attention from investors, healthcare providers, and pharmaceutical manufacturers.
-
University of Edinburgh’s Macrophage Cell Therapy slashes liver transplant need
Researchers tested the therapy through the MATCH clinical trial, which involved 50 patients with advanced liver cirrhosis.